Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rehabilitation × Genitourinary × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6 Breast 4 Gastrointestinal 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 356 pembrolizumab 284 Prednisone 258 Gemcitabine 238 Radiotherapy 222 enzalutamide 221 Nivolumab 219 Magnetic Resonance Spectroscopy 219 Cisplatin 178 Abiraterone Acetate 172 Radiosurgery 168 Leuprolide 160 Carboplatin 144 Sunitinib 143 bicalutamide 125 Specimen Handling 124 Goserelin 124 Androgen Antagonists 121 Paclitaxel 115 Ipilimumab 113 Cyclophosphamide 102 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 99 Everolimus 95 apalutamide 91 cabozantinib 89 Bevacizumab 89 abiraterone 82 Sorafenib 82 Radiation 82 atezolizumab 81

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06238596 2025-10-03

ReCaP

Azienda USL Reggio Emilia - IRCCS

Phase NA Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡